Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 StudyPHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology...